Tags : Blackstone

Takeda to Divest its Consumer Health Unit to Blackstone for

Shots: Takeda and Blackstone sign an agreement to divest it consumer health care business unit for $2.3B. The transaction expected to be closed by Mar 31, 2021 The portfolio to be divested includes OTC medicines and health products along with its lead product in the region, Alinamin. Blackstone plans to develop the business together with […]Read More

PharmaShots Weekly Snapshot (April 13 -17, 2020)

1. Sinovac Initiates the P-I Clinical Study for Vaccine Candidate Against COVID-19 Published: Apr 17, 2020 | Tags: Sinovac, Initiates, P-I, Clinical Study, Vaccine Candidate, Against, COVID-19 2. 1Health.io Launches Self-Collection Kits to Detect COVID-19 Published: Apr 16, 2020 | Tags: 1Health.io, Launches, Self-Collection Kits, Detect, COVID-19 3. Chi-Med’s Surufatinib Receives the US FDA’s Fast Track Designations […]Read More

Blackstone and Alnylam Enter into a Collaboration to Accelerate the

Shots: Blackstone to invest $2B in Alnylam that includes $1B in committed payments in exchange of 50% royalties and commercial milestones for inclisiran, ~$750M in a first lien senior secured term loan led by GSO, ~$150M for Alnylam’s cardiometabolic programs (vutrisiran and ALN-AGT) and ~$100M on purchase of Alnylam’s common stock The transaction marks the […]Read More

Ferring and Blackstone Collaborate to Establish Joint Venture Focusing on

Shots: Ferring launches a new company FerGene focusing the global development and commercialization of Nadofaragene firadenovec in the US for the patients with Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer Blackstone to invest $400M and its expertise to accelerate the future development and commercialization of Nadofaragene firadenovec while Ferring will invest up to $170M […]Read More